pharmacie et médicaments – Traitement contre la dégénérescence maculaire liée à l'âge (DMLA) sèche

This written question concerns the regulation of treatments for dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. It seeks clarification on the current regulatory landscape for these therapies. The question is posed by a French National Assembly member, indicating a focus on national-level policy and its impact on patients and the pharmaceutical sector within France.